A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

NCT03284931 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: SAGE-217 high dose
DRUG: Placebo
DRUG: SAGE-217 low dose

Sponsor

Biogen